Business
Notice of results for year ended 30 Sept 2018
Notice of results for year ended 30 Sept 2018.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 2832I Oxford BioDynamics PLC 23 November 2018 \n\n23 November 2018\nOXFORD BIODYNAMICS PLC\n(\"OBD\" or the \"Company\" or the \"Group\")\n \nNotice of results for the year ended 30 September 2018\n \nOxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, expects to announce its full year results for the year ended 30 September 2018 on Tuesday 11 December 2018.\n \nFor further details please contact: \n \n\n\n\nOxford BioDynamics Plc.\n\n\n\n\n\n+44 (0)1865 518910\n\n\n\n\nChristian Hoyer Millar, CEO\n\n\n\n\n\n\n\n\n\n\nPaul Stockdale, CFO\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nShore Capital\n\n\n\n\n\n+44 (0)20 7408 4090\n\n\n\n\nNominated Adviser and Broker \n\n\n\n\n\n\n\n\n\n\nStephane Auton\n\n\n\n\n\n\n\n\n\n\nEdward Mansfield\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFTI Consulting \n\n\n\n\n\n+44 (0)20 3727 1000\n\n\n\n\nFinancial Public Relations Advisor\n\n\n\n\n\n\n\n\n\n\nBrett Pollard\n\n\n\n\n\n\n\n\n\n\nNatalie Garland-Collins\n\n\n\n\n\n\n\n\n\n \n \nNotes for Editors\n \nAbout Oxford BioDynamics Plc\n \nOxford BioDynamics Plc (AIM: OBD) (\"Oxford BioDynamics\") is a revenue‐generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.\n \nThe Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. \n \nIn particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.\n \nOxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker \"OBD\". For mor...